Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial | Zendy

José Moltó | Zendy; Marta Valle | Zendy; Elena Ferrer | Zendy; Peré Domingo | Zendy; Adrián Curran | Zendy; José Ramón Santos | Zendy; María Gracia Mateo | Zendy; María Silvana Di Yacovo | Zendy; Cristina Miranda | Zendy; Daniel Podzamczer | Zendy; Bonaventura Clotet | Zendy; J Coll | Zendy; Sílvia Gel | Zendy; Josep M. Llibre | Zendy; Beatriz Mothe | Zendy; Eugènia Negredo | Zendy; Núria PérezÁlvarez | Zendy; Guillem Sirera | Zendy; María Silvana DiYacovo | Zendy; Nerea Rozas | Zendy; Antonia Vila | Zendy; María del Mar Gutiérrez | Zendy; Gràcia Mateo | Zendy; Joaquín Burgos | Zendy; Jordi Navarro | Zendy; Esteban Ribera | Zendy

Open Access

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

Author(s) -

José Moltó,

Marta Valle,

Elena Ferrer,

Peré Domingo,

Adrián Curran,

José Ramón Santos,

María Gracia Mateo,

María Silvana Di Yacovo,

Cristina Miranda,

Daniel Podzamczer,

Bonaventura Clotet,

J Coll,

Sílvia Gel,

Josep M. Llibre,

Beatriz Mothe,

Eugènia Negredo,

Núria PérezÁlvarez,

Guillem Sirera,

María Silvana DiYacovo,

Nerea Rozas,

Antonia Vila,

María del Mar Gutiérrez,

Gràcia Mateo,

Joaquín Burgos,

Jordi Navarro,

Esteban Ribera

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku516

Subject(s) - darunavir , medicine , discontinuation , randomized controlled trial , clinical endpoint , clinical trial , human immunodeficiency virus (hiv) , pharmacokinetics , viral load , antiretroviral therapy , immunology

Maximizing ART efficiency is of growing interest. This study assessed the efficacy, safety, pharmacokinetics and economics of a darunavir dose-reduction strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research